QTERN (SAXAGLIPTIN/DAPAGLIFLOZIN FDC) Regulatory Post-Marketing Surveillance
NCT05160974
·
clinicaltrials.gov ↗
COMPLETED
Status
679
Enrollment
INDUSTRY
Sponsor class
Conditions
Type 2 Diabetes Mellitus
Sponsor
AstraZeneca